Clinical trials · Massachusetts
Aspiration clinical trials in Massachusetts
We’re tracking 38 recruiting aspiration studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT06747117Recruiting
Removing blood clots in leg arteries with the Indigo system
This study tests a device that vacuums out blood clots from blocked leg arteries, potentially restoring blood flow without open surgery.
Worcester, MassachusettsAges 18 years+ - NCT05108896Recruiting
Testing breathing and swallowing recovery after ICU breathing support
This study looks at aspiration (food or liquid going “the wrong way” into the airway) in people who survived a serious ICU breathing problem. It may help doctors better support safe swallowing and breathing recovery after being on a breathing machine.
Boston, MassachusettsAges 18 years+ - NCT05455359RecruitingPhase 4
Tube-fed children at high risk for aspiration pneumonia
This Phase 4 study looks at gastrointestinal movement (dysmotility) and how it may increase the risk of aspiration pneumonia in children who eat through a tube and have swallowing safety problems. It may help doctors better prevent lung infections in children who cough/choke and need suction often.
Boston, MassachusettsAges 5–21 - NCT05674643Recruiting
Gastric testing during children’s surgery
This trial studies how the stomach is working in children around the time of surgery. It may help improve how doctors assess and manage stomach function to make surgery safer and more comfortable.
Boston, MassachusettsAges 2–18 - NCT06003101RecruitingPhase 3
Blood treatments for hip labrum tear surgery
This study tests whether adding platelet-rich plasma (a blood concentrate), platelet-poor plasma, or bone marrow concentrate during hip surgery helps people with a torn labrum recover better. If you need hip arthroscopy and haven't had prior hip surgery, you may be able to join.
Boston, MassachusettsAges 18 years+ - NCT04798261Recruiting
Long-term follow-up after clot removal for pulmonary embolism
This study tracks how patients do long-term after having a clot in the lung treated with a device called the Indigo Aspiration System. It aims to better understand safety and outcomes over time.
Fall River, MassachusettsAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Boston, MassachusettsAges 18 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Boston, MassachusettsAges 18–59 - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Boston, MassachusettsAges 18–75 - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Boston, MassachusettsAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Boston, MassachusettsAges Up to 30 years - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Boston, MassachusettsAges 18 years+ - NCT06751043Recruiting
Testing if fasting before a procedure is needed in ICU patients
This trial tests whether not eating before a procedure (called preoperative fasting) is better than fasting in ICU patients who are already receiving tube feedings. It aims to find out if skipping the fast can help you without causing extra risks.
Worcester, MassachusettsAges 18 years+ - NCT07303738RecruitingPhase 4
Testing bile-lowering foods for kids with feeding tubes
This trial tests if certain foods can lower bile acid levels in the upper part of the stomach for children who get most nutrition through a feeding tube. It may help understand and manage reflux symptoms related to bile.
Boston, MassachusettsAges 5–21 - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Boston, MassachusettsAges 65 years+ - NCT06232044RecruitingPhase 1/Phase 2
Testing a new drug combo for returning multiple myeloma
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Springfield, MassachusettsAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Boston, MassachusettsAges Any age - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Boston, MassachusettsAges 18–59 - NCT06317649RecruitingPhase 2
Venetoclax and HMA for older adults with FLT3-mutated AML
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Boston, MassachusettsAges 18–59 - NCT07466316RecruitingPhase 3
Comparing chemo schedules for intermediate-risk rhabdomyosarcoma
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
Boston, MassachusettsAges Up to 50 years - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Boston, MassachusettsAges Up to 12 months
Aspiration trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting aspiration studies listed above.
- Dana-Farber Cancer Institute · 12 studies
- Tufts Medical Center · 11 studies
- Beth Israel Deaconess Medical Center · 4 studies
- Massachusetts General Hospital · 4 studies
- UMass Memorial Medical Center · 4 studies
- Boston Children's Hospital · 3 studies
- Lahey Hospital and Medical Center · 3 studies
- Lahey Medical Center-Peabody · 3 studies
What taking part in a aspiration study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there aspiration clinical trials in Massachusetts?
- Yes. We're currently tracking 38 recruiting aspiration studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a aspiration study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a aspiration trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New aspiration studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.